Literature DB >> 10915140

Outcomes studies of drug induced ulcer complications: do we need them and how should they be done?

C J Hawkey1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10915140      PMCID： PMC1118282          DOI： 10.1136/bmj.321.7256.291

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  24 in total

1.  Prevention of NSAID-induced gastroduodenal mucosal injury: meta-analysis of clinical trials with misoprostol and H2-receptor antagonists.

Authors:  M Koch; L Capurso; A Dezi; F Ferrario; C Scarpignato
Journal:  Dig Dis       Date:  1995-01       Impact factor: 2.404

2.  Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2.

Authors:  C Luong; A Miller; J Barnett; J Chow; C Ramesha; M F Browner
Journal:  Nat Struct Biol       Date:  1996-11

3.  Prescribing of nonsteroidal anti-inflammatory drugs in general practice: determinants and consequences.

Authors:  C J Hawkey; D J Cullen; D C Greenwood; J V Wilson; R F Logan
Journal:  Aliment Pharmacol Ther       Date:  1997-04       Impact factor: 8.171

4.  A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group.

Authors:  N D Yeomans; Z Tulassay; L Juhász; I Rácz; J M Howard; C J van Rensburg; A J Swannell; C J Hawkey
Journal:  N Engl J Med       Date:  1998-03-12       Impact factor: 91.245

5.  Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

Authors:  C J Hawkey; J A Karrasch; L Szczepañski; D G Walker; A Barkun; A J Swannell; N D Yeomans
Journal:  N Engl J Med       Date:  1998-03-12       Impact factor: 91.245

6.  Efficacy of 12 months' misoprostol as prophylaxis against NSAID-induced gastric ulcers. A placebo-controlled trial.

Authors:  S L Elliott; N D Yeomans; R R Buchanan; R A Smallwood
Journal:  Scand J Rheumatol       Date:  1994       Impact factor: 3.641

7.  Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment.

Authors:  C Hawkey; A Kahan; K Steinbrück; C Alegre; E Baumelou; B Bégaud; J Dequeker; H Isomäki; G Littlejohn; J Mau; S Papazoglou
Journal:  Br J Rheumatol       Date:  1998-09

8.  ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1995-03-18       Impact factor: 79.321

9.  Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study.

Authors:  J B Raskin; R H White; R Jaszewski; M A Korsten; T T Schubert; J G Fort
Journal:  Am J Gastroenterol       Date:  1996-02       Impact factor: 10.864

10.  Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects.

Authors:  L S Simon; F L Lanza; P E Lipsky; R C Hubbard; S Talwalker; B D Schwartz; P C Isakson; G S Geis
Journal:  Arthritis Rheum       Date:  1998-09
View more
  2 in total

1.  Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans.

Authors:  C J Hawkey; J I Jones; C T Atherton; M M Skelly; J R Bebb; U Fagerholm; B Jonzon; P Karlsson; I T Bjarnason
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

Review 2.  Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract.

Authors:  Martin W James; Christopher J Hawkey
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.